PRECEDEX Highlights

(dexmedetomidine hydrochloride injection)

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PRECEDEX safely and effectively. See full prescribing information for PRECEDEX.

PRECEDEX™ (dexmedetomidine hydrochloride) injection, for intravenous use
PRECEDEX™ (dexmedetomidine hydrochloride) in sodium chloride injection, for intravenous use
Initial U.S. Approval: 1999

RECENT MAJOR CHANGES

Indication and Usage, Procedural Sedation (1.2)

Dosage and Administration, Recommended Dosage (2.2)

Dosage and Administration, Preparation of Solution (2.4)

Warnings and Precautions, Withdrawal (5.5)

12/2022

12/2022

08/2022

12/2022

Warnings and Precautions, Hyperthermia or Pyrexia (5.7)

08/2022

INDICATIONS AND USAGE

PRECEDEX is a alpha2-adrenergic receptor agonist indicated for:

Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer PRECEDEX by continuous infusion not to exceed 24 hours. (1.1)
Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. (1.2)
Sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures. (1.2)

DOSAGE AND ADMINISTRATION

Individualize and titrate PRECEDEX dosing to desired clinical effect. (2.1)
Administer PRECEDEX using a controlled infusion device. (2.1)
Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. (2.4)
The 80 mcg/20 mL single-dose vial, and 200 mcg/50 mL, 400 mcg/100 mL, and 1,000 mcg/250 mL single-dose bottles do not require further dilution prior to administration. (2.4)
For Adult Intensive Care Unit Sedation: Initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour. (2.2)
For Adult Procedural Sedation: Initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour. (2.2)
For Sedation of Pediatric Patients During Non-invasive Procedures: Patients 1 month to less than 2 years old initiate at 1.5 mcg/kg over 10 minutes followed by a maintenance infusion of 1.5 mcg/kg/hourand titrated to achieve desired clinical effect with dosage ranging from 0.5 to 1.5 mcg/kg/hour; patients 2 to less than 18 years old initiate at 2.0 mcg/kg over 10 minutes followed by a maintenance infusion of 1.5 mcg/kg/hourand titrated to achieve desired clinical effect with dosage ranging from 0.5 to 1.5 mcg/kg/hour. (2.2)
Alternative Doses: Recommended for patients over 65 years of age and awake fiberoptic intubation patients. (2.2)

DOSAGE FORMS AND STRENGTHS

PRECEDEX Injection, 200 mcg/2 mL (100 mcg/mL) in a single-dose vial. To be used after dilution. (3)
PRECEDEX in 0.9% Sodium Chloride Injection, 80 mcg/20 mL (4 mcg/mL) in a single-dose vial. Ready to use. (3)
PRECEDEX in 0.9% Sodium Chloride Injection, 200 mcg/50 mL, 400 mcg/100 mL, and 1,000 mcg/250 mL (4 mcg/mL) in single-dose glass bottles. Ready to use. (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

Monitoring: Continuously monitor patients while receiving PRECEDEX. (5.1)
Bradycardia and Sinus Arrest: Have occurred in young healthy volunteers with high vagal tone or with different routes of administration, e.g., rapid intravenous or bolus administration. (5.2)
Hypotension and Bradycardia: May necessitate medical intervention. May be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension, and in the elderly. Use with caution in patients with advanced heart block or severe ventricular dysfunction. (5.2)
Co-administration with Other Vasodilators or Negative Chronotropic Agents: Use with caution due to additive pharmacodynamic effects. (5.2)
Transient Hypertension: Observed primarily during the loading dose. Consider reduction in loading infusion rate. (5.3)
Arousability: Patients can become aroused/alert with stimulation; this alone should not be considered as lack of efficacy. (5.4)
Tolerance and Tachyphylaxis: Prolonged exposure to dexmedetomidine beyond 24 hours may be associated with tolerance and tachyphylaxis and a dose-related increase in adverse events. (5.6)

ADVERSE REACTIONS

The most common adverse reactions (incidence >2%) in adults are hypotension, bradycardia, and dry mouth. (6.1)
The most common adverse reactions (incidence >5%) in pediatric patients aged 1 month to less than 17 years are bradypnea, bradycardia, hypertension, and hypotension. (6.1)
Adverse reactions in adults, associated with infusions >24 hours in duration include ARDS, respiratory failure, and agitation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.

DRUG INTERACTIONS

Anesthetics, Sedatives, Hypnotics, Opioids: Enhancement of pharmacodynamic effects. Reduction in dosage of PRECEDEX or the concomitant medication may be required. (7.1)

USE IN SPECIFIC POPULATIONS

Geriatric Patients: Dose reduction should be considered. (2.2, 2.3, 5.2, 8.5)
Hepatic Impairment: Dose reduction should be considered. (2.2, 2.3, 5.8, 8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2022

Find PRECEDEX medical information:

Find PRECEDEX medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

PRECEDEX Quick Finder

Prescribing Information
Download Prescribing Information

Health Professional Information

Highlights

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use PRECEDEX safely and effectively. See full prescribing information for PRECEDEX.

PRECEDEX™ (dexmedetomidine hydrochloride) injection, for intravenous use
PRECEDEX™ (dexmedetomidine hydrochloride) in sodium chloride injection, for intravenous use
Initial U.S. Approval: 1999

RECENT MAJOR CHANGES

Indication and Usage, Procedural Sedation (1.2)

Dosage and Administration, Recommended Dosage (2.2)

Dosage and Administration, Preparation of Solution (2.4)

Warnings and Precautions, Withdrawal (5.5)

12/2022

12/2022

08/2022

12/2022

Warnings and Precautions, Hyperthermia or Pyrexia (5.7)

08/2022

INDICATIONS AND USAGE

PRECEDEX is a alpha2-adrenergic receptor agonist indicated for:

Sedation of initially intubated and mechanically ventilated adult patients during treatment in an intensive care setting. Administer PRECEDEX by continuous infusion not to exceed 24 hours. (1.1)
Sedation of non-intubated adult patients prior to and/or during surgical and other procedures. (1.2)
Sedation of non-intubated pediatric patients aged 1 month to less than 18 years prior to and during non-invasive procedures. (1.2)

DOSAGE AND ADMINISTRATION

Individualize and titrate PRECEDEX dosing to desired clinical effect. (2.1)
Administer PRECEDEX using a controlled infusion device. (2.1)
Dilute the 200 mcg/2 mL (100 mcg/mL) vial contents in 0.9% sodium chloride solution to achieve required concentration (4 mcg/mL) prior to administration. (2.4)
The 80 mcg/20 mL single-dose vial, and 200 mcg/50 mL, 400 mcg/100 mL, and 1,000 mcg/250 mL single-dose bottles do not require further dilution prior to administration. (2.4)
For Adult Intensive Care Unit Sedation: Initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion of 0.2 to 0.7 mcg/kg/hour. (2.2)
For Adult Procedural Sedation: Initiate at one mcg/kg over 10 minutes, followed by a maintenance infusion initiated at 0.6 mcg/kg/hour and titrated to achieve desired clinical effect with doses ranging from 0.2 to 1 mcg/kg/hour. (2.2)
For Sedation of Pediatric Patients During Non-invasive Procedures: Patients 1 month to less than 2 years old initiate at 1.5 mcg/kg over 10 minutes followed by a maintenance infusion of 1.5 mcg/kg/hourand titrated to achieve desired clinical effect with dosage ranging from 0.5 to 1.5 mcg/kg/hour; patients 2 to less than 18 years old initiate at 2.0 mcg/kg over 10 minutes followed by a maintenance infusion of 1.5 mcg/kg/hourand titrated to achieve desired clinical effect with dosage ranging from 0.5 to 1.5 mcg/kg/hour. (2.2)
Alternative Doses: Recommended for patients over 65 years of age and awake fiberoptic intubation patients. (2.2)

DOSAGE FORMS AND STRENGTHS

PRECEDEX Injection, 200 mcg/2 mL (100 mcg/mL) in a single-dose vial. To be used after dilution. (3)
PRECEDEX in 0.9% Sodium Chloride Injection, 80 mcg/20 mL (4 mcg/mL) in a single-dose vial. Ready to use. (3)
PRECEDEX in 0.9% Sodium Chloride Injection, 200 mcg/50 mL, 400 mcg/100 mL, and 1,000 mcg/250 mL (4 mcg/mL) in single-dose glass bottles. Ready to use. (3)

CONTRAINDICATIONS

None. (4)

WARNINGS AND PRECAUTIONS

Monitoring: Continuously monitor patients while receiving PRECEDEX. (5.1)
Bradycardia and Sinus Arrest: Have occurred in young healthy volunteers with high vagal tone or with different routes of administration, e.g., rapid intravenous or bolus administration. (5.2)
Hypotension and Bradycardia: May necessitate medical intervention. May be more pronounced in patients with hypovolemia, diabetes mellitus, or chronic hypertension, and in the elderly. Use with caution in patients with advanced heart block or severe ventricular dysfunction. (5.2)
Co-administration with Other Vasodilators or Negative Chronotropic Agents: Use with caution due to additive pharmacodynamic effects. (5.2)
Transient Hypertension: Observed primarily during the loading dose. Consider reduction in loading infusion rate. (5.3)
Arousability: Patients can become aroused/alert with stimulation; this alone should not be considered as lack of efficacy. (5.4)
Tolerance and Tachyphylaxis: Prolonged exposure to dexmedetomidine beyond 24 hours may be associated with tolerance and tachyphylaxis and a dose-related increase in adverse events. (5.6)

ADVERSE REACTIONS

The most common adverse reactions (incidence >2%) in adults are hypotension, bradycardia, and dry mouth. (6.1)
The most common adverse reactions (incidence >5%) in pediatric patients aged 1 month to less than 17 years are bradypnea, bradycardia, hypertension, and hypotension. (6.1)
Adverse reactions in adults, associated with infusions >24 hours in duration include ARDS, respiratory failure, and agitation. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact Hospira, Inc. at 1-800-441-4100, or FDA at 1-800-FDA-1088 or https://www.fda.gov/medwatch.

DRUG INTERACTIONS

Anesthetics, Sedatives, Hypnotics, Opioids: Enhancement of pharmacodynamic effects. Reduction in dosage of PRECEDEX or the concomitant medication may be required. (7.1)

USE IN SPECIFIC POPULATIONS

Geriatric Patients: Dose reduction should be considered. (2.2, 2.3, 5.2, 8.5)
Hepatic Impairment: Dose reduction should be considered. (2.2, 2.3, 5.8, 8.6)

See 17 for PATIENT COUNSELING INFORMATION.

Revised: 12/2022

Medication Guide

Health Professional Information

{{section_name_patient}}

{{section_body_html_patient}}

Resources

Didn’t find what you were looking for? Contact us.

MI Digital Assistant

Chat online with Pfizer Medical Information regarding your inquiry on a Pfizer medicine.

Call 800-438-1985*

*Speak with a Pfizer Medical Information Professional regarding your medical inquiry. Available 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

To report an adverse event related to the Pfizer-BioNTech COVID-19 Vaccine, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

If you cannot use the above website, or would like to report an adverse event related to a different Pfizer product, please call Pfizer Safety at (800) 438-1985.

FDA Medwatch

You may also contact the U.S. Food and Drug Administration (FDA) directly to report adverse events or product quality concerns either online at www.fda.gov/medwatch or call (800) 822-7967.